Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesothelin-targeted OC-IgT
- Development stage
- Unknown
- Lead developer
- Shenzhen Geno-Immune Medical Institute
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intratumoral
01
Overview
mesothelin-targeted OC-IgT is an autologous, genetically engineered T-cell therapy (immunogene-modified T cells, or IgT) designed to target mesothelin-expressing ovarian cancer cells. Developed by the Shenzhen Geno-Immune Medical Institute in collaboration with Xuefeng Wang, this cell therapy involves isolating a patient's T lymphocytes, genetically modifying them to express a chimeric antigen receptor (CAR) targeting mesothelin, and infusing them back into the patient. Mesothelin is a cell-surface glycoprotein highly overexpressed in epithelial ovarian cancers but minimally expressed in normal tissues, making it a promising target for adoptive immunotherapy. The therapy is being evaluated in clinical trials in China for patients with recurrent or refractory ovarian cancer to assess its safety, tolerability, and antitumor efficacy.
- Other names
- mesothelin-targeted autologous ovarian cancer immunogene-modified T cellsmesothelin-targeted IgTmesothelin-targeted OC-IgT cellsmesothelin-targeted ovarian cancer immunogene-modified T cells
02
Targets
Mesothelin
Beyond the preview
Go deeper on mesothelin-targeted OC-IgT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesothelin-targeted OC-IgT.